Polaryx Therapeutics, Inc. (PLYX) Key Metrics
PLYX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $93.7M
- Enterprise value
- $106.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 9.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
PLYX key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPLYX returns How much profit the business earns on the capital it uses.
PLYX per-share figures Results divided by the shares outstanding at year-end.
PLYX financial health Debt, liquidity and how easily interest is covered.
PLYX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PLYX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PLYX key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Per share | |||
| Revenue per share | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.19 | −$0.16 | −$0.02 |
| Operating cash flow per share | −$0.08 | −$0.01 | −$0.00 |
| Free cash flow per share | −$0.08 | −$0.01 | −$0.00 |
| Cash per share | $0.11 | $0.02 | $0.00 |
| Book value per share | $0.10 | $0.02 | $0.01 |
| Tangible book value per share | $0.10 | $0.02 | $0.01 |
| Capex per share | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | $0.00 |
| Shares outstanding | 47.3M | 189.4M | 189.4M |
| Change in shares outstanding | −75.0% | 0.0% | — |
| Returns & profitability | |||
| Return on equity (ROE) | −193.7% | — | −295.9% |
| Return on invested capital (ROIC) | — | −460.3% | −212.9% |
| Return on assets (ROA) | −172.4% | −829.9% | −163.2% |
| Return on tangible assets | −165.8% | −607.0% | −163.2% |
| Financial health | |||
| Total debt | — | — | $128,000 |
| Cash & short-term investments | $5.1M | $4.6M | $2,000 |
| Net debt | −$5.1M | −$4.6M | $126,000 |
| Debt / equity | — | — | 0.10 |
| Debt / assets | — | — | 0.06 |
| Current ratio | 8.55 | 17.30 | 2.23 |
| Quick ratio | 8.55 | 17.30 | 2.23 |
| Working capital | $4.6M | $4.7M | $1.3M |
| Invested capital | −$578,000 | $91,000 | $1.4M |
| Tangible asset value | $4.6M | $4.7M | $1.3M |
| Net current asset value | $4.3M | $4.7M | $1.3M |
| Graham net-net per share | $0.09 | $0.02 | −$0.01 |
| Efficiency | |||
| Asset turnover | 0.00 | 0.00 | 0.00 |
| Average payables | $271,000 | $272,500 | $473,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% |
Computed from PLYX's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PLYX valuation and financial ratios
Polaryx Therapeutics earned a return on equity of −193.7% in fiscal 2025.
See the PLYX income statement, the PLYX chart for price history, or the PLYX stock overview for the latest quote and news.
PLYX key metrics FAQ
What is Polaryx Therapeutics's return on equity?
Polaryx Therapeutics's return on equity (ROE) was −193.7% in fiscal 2025: net income of -$9.0 million on average shareholders' equity of $4.6 million.
What is Polaryx Therapeutics's current ratio?
Polaryx Therapeutics's current ratio was 8.55 at the end of fiscal 2025: current assets were 8.55 times current liabilities.